Clinical Trial Update: A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Regeneron is evaluating REGN5093 in adults with MET-altered advanced non-small cell lung cancer in a Phase 1/2 study. The trial status is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• REGN5093

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: NSCLC | Phase 1, Phase 2 | Status: RECRUITING